nach oben

Endocrine

Erschienen in:

11.04.2020 | Meta-Analysis

Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis

verfasst von: Mengying Qu, Siyuan Wan, Bingxuan Ren, Huaiyong Wu, Lixiang Liu, Hongmei Shen

Erschienen in: Endocrine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the association between the thyroid stimulating hormone receptor (TSHR) gene methylation and human papillary thyroid cancer (PTC), as well as PTC related clinicopathological indicators.

Methods

We searched PubMed, Embase, Medline, and Web of Science databases through computer for articles published in English on association between methylation of TSHR gene and PTC. Articles published in Chinese were searched in China National Knowledge Infrastructure (CNKI), WanFang, China Biology Medicine (CBM) disc, and WeiPu databases. Database search took place in the 4th week of October.

Results

Totally 914 samples from 14 case-control studies were included in our meta-analysis. The methylation rate of TSHR gene in PTC group was significantly greater than that in control group (OR = 6.45, 95% CI 3.03, 13.71, P < 0.001). The subgroup analysis results showed the incidence of TSHR gene methylation was higher in autologous controls (OR = 16.39, 95% CI 8.83, 30.42, P < 0.001), Asian races (OR = 8.26, 95% CI 3.54, 19.23, P < 0.001), and Chinese (OR = 11.40, 95% CI 5.56, 23.39, P < 0.001). Hierarchical analysis of PTC related clinicopathological indicators showed that TSHR gene methylation rate are higher in PTC patients over 45 years (OR = 1.65, 95% CI 1.07, 2.55, P < 0.05) and lymph node metastasis (OR = 5.36, 95% CI 1.54, 18.67, P < 0.01). In addition, the occurrence of TSHR gene methylation had also been shown to be related to the clinical stage (OR = 0.23, 95% CI 0.07, 0.70, P < 0.05) and size (OR = 0.19, 95% CI 0.11, 0.32, P < 0.01) of tumors. The result of sensitivity analysis showed the combined results of the studies included in the meta-analysis were fairly stable. Begg’s and Egger’s tests also suggested that there was no significance publication bias (P > 0.1).

Conclusions

The rate of TSHR gene methylation is higher in PTC and it may be associated with the pathogenesis of human PTC, suggesting that TSHR gene may be a candidate marker for PTC diagnosis. In addition, the occurrence of TSHR gene methylation in PTC patients is closely related to age, lymph node metastasis, clinical stage, and tumor size, suggesting that TSHR gene may be used as an index to judge the severity of PTC.

Y. Pang, Z. Lu, P. Jiang, Y. Guan, X. Jin, H. Shen, Iodine-rich diet and thyroid cancer: a meta-analysis. Chin. J. Endemiol. 36(11), 840–845 (2017). https://doi.org/10.3760/cma.j.issn.2095-4255.2017.11.014CrossRef

F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). https://doi.org/10.3322/caac.21492CrossRefPubMed

M.I. Abdullah, S.M. Junit, K.L. Ng, J.J. Jayapalan, B. Karikalan, O.H. Hashim, Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int. J. Med. Sci. 16(3), 450–460 (2019). https://doi.org/10.7150/ijms.29935CrossRefPubMedPubMedCentral

Y. Pang, Y. Guan, X. Jin, H. Shen, L. Liu, Q. Jia, F. Meng, X. Zhang, Association of TSHR gene copy number variation with TSH abnormalities. Biol. Trace Elem. Res. 186(1), 85–90 (2018). https://doi.org/10.1007/s12011-018-1300-7CrossRefPubMed

P.A. Jones, S.B. Baylin, The epigenomics of cancer. Cell 128(4), 683–692 (2007). https://doi.org/10.1016/j.cell.2007.01.029CrossRefPubMedPubMedCentral

K. Kartal, S. Onder, K. Kosemehmetoglu, S. Kilickap, Y.G. Tezel, V. Kaynaroglu, Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material. BMC Cancer 15, 824 (2015). https://doi.org/10.1186/s12885-015-1861-1CrossRefPubMedPubMedCentral

M. Xing, H. Usadel, Y. Cohen, Y. Tokumaru, Z. Guo, W.B. Westra, B.C. Tong, G. Tallini, R. Udelsman, J.A. Califano, P.W. Ladenson, D. Sidransky, Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 63(9), 2316–2321 (2003)PubMed

U. Schagdarsurengin, O. Gimm, H. Dralle, C. Hoang-Vu, R. Dammann, CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16(7), 633–642 (2006). https://doi.org/10.1089/thy.2006.16.633CrossRefPubMed

J. Mohammadi-asl, B. Larijani, Z. Khorgami, S.M. Tavangar, V. Haghpanah, M. Kheirollahi, P. Mehdipour, Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARbeta2 genes in papillary thyroid carcinoma. Med. Oncol. 28(4), 1123–1128 (2011). https://doi.org/10.1007/s12032-010-9587-zCrossRefPubMed

10.

Y. Huang, Y. Luo, Z. Ren, H. Zhang, J. Deng, The early diagnosis value of TSHR, RARβ2 and RASSF1A promoter methylation in plasma circulating DNA in thyroid carcinoma. Jiangxi Med. J. 52(11), 1117–1119+1127 (2017). https://doi.org/10.3969/j.issn.1006-2238.2017.11.003CrossRef

11.

A. Stang, Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25(9), 603–605 (2010). https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

12.

J. Xiong, Y. Li, K. Huang, M. Lu, H. Shi, L. Ma, A. Luo, S. Yang, Z. Lu, J. Zhang, L. Yang, S. Wang, Association between DAPK1 promoter methylation and cervical cancer: a meta-analysis. PLoS One 9(9), e107272–e107272 (2014). https://doi.org/10.1371/journal.pone.0107272CrossRefPubMedPubMedCentral

13.

F. Khatami, B. Larijani, R. Heshmat, A. Keshtkar, M. Mohammadamoli, L. Teimoori-Toolabi, S. Nasiri, S.M. Tavangar, Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PLoS One 12(9), e0184892 (2017). https://doi.org/10.1371/journal.pone.0184892CrossRefPubMedPubMedCentral

14.

G. Wen, H. Wang, Z. Zhong, Associations of RASSF1A, RARbeta, and CDH1 promoter hypermethylation with oral cancer risk: a PRISMA-compliant meta-analysis. Medicine 97(11), e9971 (2018). https://doi.org/10.1097/MD.0000000000009971CrossRefPubMedPubMedCentral

15.

Y. Dai, D. Cai, H. Chen, H. Zhang, Z. Zhang, J. Li, The relevance between the promoter hypermethylation of tshr and p16 gene and clinicopathological parameters in human papillary thyroid carcinoma. J. Cap. Med. Univ. 33(03), 83–87 (2012). https://doi.org/10.3969/j.issn.10067795.2012.03.016CrossRef

16.

S. Zhao, TSHR gene methylation level of papillary thyroid carcinoma and its clinical significance, Master (Hebei Medical University, China, 2014)

17.

J. Xu, X. Guo, M. Ge, The relation between methylation of TSHR and NIS gene promoter region correlated and aggressiveness in papillary thyroid carcinoma. China Mod. Dr. 54(21), 1–5 (2016)

18.

X. Shi, J. Cheng, H. Guan, W. Teng, Hypermethylation and protein expression of TSHR and NIS genes in papillary thyroid cancer and their association with BRAF mutation. J. China Med. Univ. 38(06), 401–404 (2009). CNKI:SUN:ZGYK.0.2009-06-002

19.

J. Tang, X. Li, Methylation of TSHR gene promoter in papillary thyroid carcinoma. J. Med. Res. 39(4), 77–79 (2010). https://doi.org/10.3969/j.issn.1673-548X.2010.04.026CrossRef

20.

Z. Wang, K. Feng, Relationship between methylation of TSHR and NIS gene promoter regions and clinicopathological characteristics in thyroid papillary carcinoma. Shandong Med. J. 57(34), 83–85 (2017). https://doi.org/10.3969/j.issn.1002-266X.2017.34.028CrossRef

21.

C. Zheng, X. Lu, Z. Ling, M. Ge, Methylation of TSHR gene promoter in papillary thyroid carcinoma and its clinical significance. J. Chin. Oncol. 23(4), 257–261 (2017). https://doi.org/10.11735/j.issn.1671-170X.2017.04.B001CrossRef

22.

J.A. Smith, C.Y. Fan, C. Zou, D. Bodenner, M.S. Kokoska, Methylation status of genes in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 133(10), 1006–1011 (2007). https://doi.org/10.1001/archotol.133.10.1006CrossRefPubMed

23.

M.S. Khan, A.A. Pandith, S.R. Masoodi, K.A. Wani, M. Ul Hussain, S. Mudassar, Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status. Endocrine 47(2), 449–455 (2014). https://doi.org/10.1007/s12020-014-0319-6CrossRefPubMed

24.

X. Shi, H. Shen, Relationship between gene copy number variation of PI3K/AKT signaling pathway and thyroid cancer: a recent advance. Chin. J. Endemiol. 38(1), 83–86 (2019). https://doi.org/10.3760/ema.j.issn.2095-4255.2019.01.021CrossRef

25.

C. Zafon Llopis, J. Gil, B. Perez-Gonzalez, M. Jorda, DNA methylation in thyroid cancer. Endocr. Relat. Cancer (2019). https://doi.org/10.1530/ERC-19-0093

26.

M. Brait, M. Loyo, E. Rosenbaum, K.L. Ostrow, A. Markova, S. Papagerakis, M. Zahurak, S.M. Goodman, M. Zeiger, D. Sidransky, C.B. Umbricht, M.O. Hoque, Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics 7(7), 710–719 (2012). https://doi.org/10.4161/epi.20524CrossRefPubMedPubMedCentral

27.

J.K. Stephen, K.M. Chen, J. Merritt, D. Chitale, G. Divine, M.J. Worsham, Methylation markers differentiate thyroid cancer from benign nodules. J. Endocrinol. Investig. 41(2), 163–170 (2018). https://doi.org/10.1007/s40618-017-0702-2CrossRef

28.

S. Zhang, The expression of the thyroid stimulating hormone receptor in papillary thyroid carcinoma subtypes and its clinical significance, Master (Hebei Medical University, China, 2016)

29.

Y. Ma, L. Liu, M. Shen, Expression of NIS and TSHR mRNA in papillary thyroid carcinomas. J. Med. Postgrad. 20(7), 699–701 (2012). https://doi.org/10.3969/j.issn.1008-8199.2012.07.005CrossRef

30.

W.G. Kim, X. Zhu, D.W. Kim, L. Zhang, E. Kebebew, S.Y. Cheng, Reactivation of the silenced thyroid hormone receptor beta gene expression delays thyroid tumor progression. Endocrinology 154(1), 25–35 (2013). https://doi.org/10.1210/en.2012-1728CrossRefPubMed

31.

C. Zhang, Q. Huo, C. Li, Z. Zhou, Q. Wu, Association between methylation of TSHR gene and papillary thyroid carcinoma: a meta analysis. Chin. Gen. Pract. 16(10A), 3371–3375 (2013). https://doi.org/10.3969/j.issn.1007-9572.2013.10.025CrossRef

32.

T.R. Liu, X. Su, W.S. Qiu, W.C. Chen, Q.Q. Men, L. Zou, Z.Q. Li, X.Y. Fu, A.K. Yang, Thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma. Eur. Rev. Med. Pharmacol. Sci. 20(17), 3582–3591 (2016)PubMed

33.

M. Gao, The expression and significance of TSHR, BRAF and NDRG2 in papillary thyroid carcinoma, Master (Hebei Medical University, China, 2018)

Titel: Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis
verfasst von: Mengying Qu
Siyuan Wan
Bingxuan Ren
Huaiyong Wu
Lixiang Liu
Hongmei Shen
Publikationsdatum: 11.04.2020
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02284-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c

Correction to: MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives

How do self-care maintenance, self-care monitoring, and self-care management affect glycated haemoglobin in adults with type 2 diabetes? A multicentre observational study

Acceleration of BRAFV600E-induced thyroid carcinogenesis by TGFβ signal deficiency in mice

Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation